Egetis receives FDA breakthrough therapy designation for tiratricol for MCT8 deficiency

Egetis Therapeutics

15 July 2025 - Egetis Therapeutics today announced that the US FDA has granted breakthrough therapy designation for tiratricol, as a treatment for monocarboxylate transporter 8 (MCT8) deficiency.

Read Egetis Therapeutics press release

Michael Wonder

Posted by:

Michael Wonder